

Supplemental Table 1: Clinical characteristics of HCV DAA-treated longitudinal cohort

Parameters	HCV Infected at DAA Therapy Start n=16
Age, years¹	64 (58-67)
Gender; No. (%)	
Male	15 (94%)
Female	1 (6%)
Race/ethnicity; No. (%)	
Black	9 (44%)
White	7 (56%)
Other	0 (0%)
Albumin level (g/dL)	3.6 (3.5;3.9)
ALT level (U/L)	45 (35; 61)
AST level (U/L)	31 (30; 45)
Platelets (x10⁹/L)	225 (186; 279)
APRI; No. (%)	
<0.4	6 (55%)
0.4-1.5	4 (36%)
>1.5	1 (9%)
Fibrosis 4 index	1.7 (1.3; 2.4)
Transient Elastography score	5 (4.4,6.0)
Transient Elastography score (%)	
<9.5	11 (100%)
9.5-12.5	0 (0%)
>12.5	0 (0%)
HCV Genotype; No. (%)	
1a	11 (69%)
1b	3 (19%)

2

2 (12%)

Plasma HCV RNA level (IU/L)

3,014,233 (311,195; 4,767,721)

Median (25th;75th percentiles) shown unless otherwise indicated